New Two-Drug attack on tough head and neck cancers
NCT ID NCT06769698
Summary
This study is testing whether adding an experimental drug called fianlimab to an existing cancer drug (cemiplimab) works better for treating advanced head and neck cancer that has returned or spread. It will involve about 120 people whose cancer has not been treated for its advanced stage and who have a specific biomarker (PD-L1). The main goal is to see if the two-drug combination shrinks tumors more effectively than the single drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Joe Arrington Cancer Research & Treatment Center
RECRUITINGLubbock, Texas, 79410, United States
-
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Conditions
Explore the condition pages connected to this study.